Edition:
India

Profile: Cytosorbents Corp (CTSO.OQ)

CTSO.OQ on NASDAQ Stock Exchange Capital Market

7.49USD
1:30am IST
Change (% chg)

$-0.14 (-1.83%)
Prev Close
$7.63
Open
$7.47
Day's High
$7.85
Day's Low
$7.47
Volume
83,669
Avg. Vol
32,210
52-wk High
$14.90
52-wk Low
$5.86

CytoSorbents Corporation, incorporated on April 25, 2002, is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.

The Company also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others. The HemoDefend technology platform is a development-stage blood purification system that removes contaminants in transfused blood products. HemoDefend consists of a mixture of proprietary porous polymer beads that target the removal of contaminants that cause transfusion reactions or cause disease in patients. The HemoDefend beads are intended to use in multiple configurations, including as a common in-line filter between the blood bag and the patient, as well as a Beads in a Bag treatment configuration, where the beads are placed directly into a blood storage bag. ContrastSorb is a development-stage blood purification technology that is being optimized for the removal of intravenous radiocontrast (IV contrast) from blood in order to prevent contrast-induced nephropathy (CIN). DrugSorb is a development-stage blood purification technology that is designed to remove various drugs and chemicals from blood for the treatment of drug overdose and drug toxicity. The BetaSorb filter is designed for use with renal replacement therapy in end-stage renal disease patients to remove mid-molecular weight toxins. BetaSorb utilizes an adsorbent polymer packed into a shaped and constructed cartridge.

The Company competes with Toray Industries, Spectral Medical Inc, Fresenius, Baxter International, Inc, Bellco S.R.L., Hemolife Medical Inc., Kaneka Corporation, Ube Industries, Ltd, CytoPherx Inc., ExThera Medical Corporation, PLC Medical Systems, Inc., Pall Corporation, Terumo Medical Corporation, Hemerus Corporation, Arbios Systems, Inc., Nephros, Gambro AB and Hemocleanse Technologies, LLC.

Company Address

Cytosorbents Corp

7 Deerpark Dr Ste K
MONMOUTH JUNCTION   NJ   08852-1977

Company Web Links